Aktuelles zur Therapie mit GLP-1-Rezeptoragonisten bei Patienten mit Diabetes mellitus Typ 2

Ther Umsch. 2017;74(8):433-439. doi: 10.1024/0040-5930/a000937.

[Article in German]

Authors

Stefan Fischli¹, Christoph Henzen¹

Affiliation

¹ 1 Abteilung für Endokrinologie, Diabetologie und Klinische Ernährung, Departement Medizin, Kantonsspital Luzern.

PMID: 29461151
DOI: 10.1024/0040-5930/a000937

No abstract available

Publication types

Comparative Study
Review

MeSH terms

Blood Glucose / metabolism
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Drug Therapy, Combination
Glucagon-Like Peptide-1 Receptor / agonists*
Glucagon-Like Peptides / adverse effects
Glucagon-Like Peptides / therapeutic use
Hypoglycemic Agents / adverse effects*
Hypoglycemic Agents / therapeutic use*
Infusions, Intravenous
Insulin / adverse effects
Insulin / blood
Insulin / therapeutic use
Liraglutide / adverse effects
Liraglutide / therapeutic use
Patient Selection
Risk Factors
Structure-Activity Relationship
Weight Loss / drug effects

Substances

Blood Glucose
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Insulin
semaglutide
Glucagon-Like Peptides
Liraglutide